首页 | 官方网站   微博 | 高级检索  
     

壮肾固精方联合黄芪注射液足三里穴位注射对脾肾气虚型蛋白尿患者的影响
引用本文:冯敏坚,刘新,刘立昌,李桂珍.壮肾固精方联合黄芪注射液足三里穴位注射对脾肾气虚型蛋白尿患者的影响[J].中外医疗,2014(17):3-5.
作者姓名:冯敏坚  刘新  刘立昌  李桂珍
作者单位:广东省中医院珠海医院血透室,广东珠海519000
摘    要:目的:探讨壮肾固精方联合黄芪注射液足三里穴位注射对脾肾气虚型蛋白尿患者的影响。方法45例蛋白尿患者随机分为观察组和对照组,对照组予常规治疗,观察组在对照组基础上予口服壮肾固精方及黄芪注射液足三里穴位注射,观察两组治疗前后24 h尿蛋白定量(24H-UPRO),、尿微量白蛋白(MAU)、血浆白蛋白(ALB)变化。结果观察组与对照组治疗前年龄、24 h尿蛋白定量、尿微量白蛋白无显著性差异,治疗后观察组24 h尿蛋白定量(977.9±795.4) mg/24 h、尿微量白蛋白(144.6±128.4) mg/L 显著低于对照组(1619.8±1135.4) mg/24 h、(250.0±197.9) mg/L。观察组治疗后的24 h 尿蛋白定量(977.9±795.4) mg/24 h、尿微量白蛋白(144.6±128.4) mg/L较治疗前(1757.8±1113.5) mg/24 h、(369.1±395.5) mg/L)显著降低,而治疗后血浆白蛋白(42.2±5.1) mg/24 h则较治疗前(40.7±6.3) g/L有所升高。结论壮肾固精方联合黄芪注射液足三里穴位注射可有效减少脾肾气虚型蛋白尿患者的蛋白尿。

关 键 词:壮肾固精方  黄芪注射液  足三里  蛋白尿

Effect of ZhuangShen GuJingFang Combined with Injecting Astragalus In-jection at Zusanli Point on Proteinuria Patients of Spleen-Kidney Qi Deficiency Type
FENG Minjian,LIU Xin,LIU Lichang,LI Guizhen.Effect of ZhuangShen GuJingFang Combined with Injecting Astragalus In-jection at Zusanli Point on Proteinuria Patients of Spleen-Kidney Qi Deficiency Type[J].China Foreign Medical Treatment,2014(17):3-5.
Authors:FENG Minjian  LIU Xin  LIU Lichang  LI Guizhen
Affiliation:(Hemodialysis Room, Zhuhai Hospital of Guangdong Hospital of TCM, Zhuhai, Guangdong Province, 519000, China)
Abstract:Objective To investigate the efficacy of ZhuangShen GuJingFang combined with injecting Astragalus Injection at Zu-sanli Point on proteinuria patients of Spleen-Kidney Qi Deficiency Type. Methods 45 proteinuria patients who met the study cri-teria were randomly divided into observation group and control group. Two groups received conventional treatment. In addition, the observation group received ZhuangShen GuJingFang and injecting Astragalus Injection at Zusanli Point for two weeks. The changes of 24 hours urine protein (24H-UPRO), microalbuminuria(MAU), plasma-albumin(ALB) of two groups before and after the treat-ment were observed. Results Before the treatment, there were no statistically significant differences in age, 24H-UPRO, MAU be-tween the observation group and the control group, after treatment, the 24H-UPRO, MAU of the observation group was (977.9 ± 795.4 mg/24h), (144.6 ±128.4 mg/L) respectively, which was significantly lower than the control group's (1619.8 ±1135.4mg/24h), (250.0±197.9mg/L) respectively. The 24H-UPRO(977.9±795.4 mg/24h), and MAU(144.6±128.4 mg/L) of the observation group af-ter treatment was much lower than 24H-UPRO (1757.8±1113.5mg/24h), MAU(369.1±395.5mg/L) before treatment, but plasma-al-bumin (42.2±5.1 mg/24h) was higher than that (40.7±6.3 g/L)before the treatment. Conclusion ZhuangShen GuJingFang and in-jecting Astragalus Injection at Zusanli Point benefited proteinuria patients of Spleen-Kidney Qi Deficiency Type.
Keywords:ZhuangShen GuJingFang  Astragalus Injection  Zusanli Point  Proteinuria
本文献已被 维普 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司    京ICP备09084417号-23

京公网安备 11010802026262号